Ethic Inc. Has $523,000 Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Ethic Inc. reduced its stake in Alnylam Pharmaceuticals by 58.2% in the first quarter, selling 2,843 shares, resulting in holdings valued at $523,000.
• Alnylam Pharmaceuticals reported $0.32 EPS for the last quarter, outperforming estimates of ($0.54) and marking a 17.3% revenue increase compared to the previous year.
• Recent analyst ratings show broad support, with 22 analysts giving a Buy rating and price targets ranging up to $490 according to Oppenheimer.

Ethic Inc. decreased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 58.2% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 2,043 shares of the biopharmaceutical company's stock after selling 2,843 shares during the period. Ethic Inc.'s holdings in Alnylam Pharmaceuticals were worth $523,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Park Square Financial Group LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $28,000. Whipplewood Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares during the period. Bessemer Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares during the period. Colonial Trust Co SC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $35,000. Finally, Washington Trust Advisors Inc. lifted its position in shares of Alnylam Pharmaceuticals by 53.5% in the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after acquiring an additional 61 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Trading Up 0.7%

Shares of NASDAQ ALNY traded up $2.98 during midday trading on Wednesday, hitting $454.18. The stock had a trading volume of 906,724 shares, compared to its average volume of 1,431,713. The company's 50-day simple moving average is $369.03 and its 200 day simple moving average is $300.28. The firm has a market cap of $59.53 billion, a P/E ratio of -183.88 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $469.81. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. The company had revenue of $773,689 billion during the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business's revenue for the quarter was up 17.3% on a year-over-year basis. During the same period last year, the firm earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling

In related news, EVP Kevin Joseph Fitzgerald sold 1,396 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $632,764.92. Following the completion of the sale, the executive vice president directly owned 22,719 shares of the company's stock, valued at $10,297,841.13. The trade was a 5.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Yvonne Greenstreet sold 6,979 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $3,163,371.33. Following the sale, the chief executive officer directly owned 56,221 shares of the company's stock, valued at approximately $25,483,292.67. This trade represents a 11.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 108,531 shares of company stock worth $41,087,238. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ALNY. Bank of America raised their price objective on Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a "buy" rating in a research report on Friday, July 11th. Needham & Company LLC raised their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. JPMorgan Chase & Co. raised their target price on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. UBS Group raised their target price on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Finally, Raymond James Financial initiated coverage on Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They set an "outperform" rating and a $370.00 target price for the company. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $405.33.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.